Comprehensive Data Stream Draft SOW_RFI..pdf
PDF 184 KB Posted
- Attached to
- Comprehensive Data Management & Streamlining Solution for Business-Critical Data (Data Stream) Federal contract opportunity
- Solicitation number
- FDA-RFI-27-1251190
About this file
This is a Request for Information (RFI) issued by the FDA's Center for Tobacco Products (CTP) seeking contractor support for developing a product-centric data management solution for tobacco product submissions and regulatory reviews.
The CTP currently organizes submission data around individual submissions rather than products, creating inefficiencies in reviewer workflows. The objective is to deliver evidence-based findings and prototype capabilities enabling product-centric navigation and selective structuring of submission content. Success requires: verified understanding of CTP's submission data sources and constraints; a CTP-specific product definition and lifecycle framework grounded in empirical evidence; feasibility analysis for associating product representations across submissions when identifiers are missing or unstable; and AI-enabled metadata tagging, prototypes, documentation, and integration-readiness artifacts. The scope is limited to discovery, data modeling, definition, feasibility analysis, and proof-of-concept activities. Key tasks include comprehensive data inventory and baseline assessment of the current submission data landscape; development of a product definition framework and cross-submission linking methodology; creation of one or more prototype capabilities assisting reviewer workflow; optional proof-of-concept demonstration with integration readiness artifacts; and findings and options analysis for future planning. The contract is firm fixed-price with a 12-month period of performance. The contractor must provide project management support including a project plan, kickoff meeting within 10 business days of award, monthly status reports, agile roadmap, staffing plan, quality assurance surveillance plan, and repository maintenance using SharePoint. All deliverables shall be owned solely by FDA and provided in Word, PowerPoint, or other approved formats per an approved project schedule.
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| RFI_Data Stream.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Department of Health and Human Services
Food & Drug Administration (FDA)
Center for Tobacco Products (CTP)
Request for Information
Comprehensive Data Management & Streamlining Solution for Business-Critical Data
(Data Stream)
Tobacco Product-Centric Data Modeling and AI Capabilities
1 Introduction
1.1 Background
To protect the public health of the U.S. population and create a healthier future, the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), signed into law on June 22, 2009, gives FDA authority to regulate the manufacture, distribution, and marketing of tobacco products. The FDA Center for Tobacco Products (CTP) is responsible for regulating tobacco products and reviewing product marketing applications submitted by industry. A single marketing application submission to CTP may include information on one or many tobacco products. Review of a single tobacco product may require finding and assessing information from one or many submissions including original and amendment submissions.
Review of marketing applications requires understanding the health risks of each individual tobacco product. The health risks of tobacco products are not solely dependent on the measurable toxicity of tobacco products, but also on the way the products are used and on factors that promote or limit use.
CTP’s current data environment is primarily organized around individual submissions rather than products. Multiple submissions related to the same product, including resubmissions and incremental changes in amendments, are not consistently or easily linked, and tobacco products do not always have stable identifiers across systems or submissions. This limits the ability to view products longitudinally, understand product evolution over time, and efficiently support reviewer and analyst workflows.
CTP is seeking a product-centric approach that can improve reviewer navigation and reduce manual effort required to locate, interpret, and compare information across submission events.
1.2 Objective
The objective of this contract is to deliver evidence-based findings and one or more prototype capabilities that enable product-centric navigation and selective structuring of submission content to support reviewer workflows. Success will be demonstrated through:
1. A verified understanding of CTP's submission-related data sources and constraints
2. A CTP-specific product definition and lifecycle framework grounded in empirical evidence
3. Feasibility analysis for associating product representations across submissions when identifiers are missing or unstable
4. AI-enabled metadata tagging, prototypes, documentation, and integration-readiness artifacts suitable for FDA evaluation and for existing and new system incorporations.
1.3 Purpose
This Performance Work Statement (PWS) defines the requirements for contractor support to the Food and Drug Administration (FDA), Center for Tobacco Products (CTP) in developing a product-centric data approach that improves visibility, consistency, and efficiency across tobacco product submissions and reviews. A foundational and enabling element of this effort is to inventory, assess, and understand
CTP’s existing submission-related data assets, including what data exists, where it resides, how it is structured, and how it is currently used, in order to establish a factual baseline for all subsequent analysis.
2 SCOPE
The scope is to identify and determine whether, and under what conditions, AI-assisted approaches could support more end-to-end product-centric submission and product lifecycle. The scope is limited to discovery, data modeling, definition, feasibility analysis, and proof-of-concept activities necessary to inform future planning and investment decisions.
At a minimum, the Contractor shall address the following scope elements:
1. Data Inventory and Assessment
An inventory and characterization of relevant structured and unstructured data assets, including submissions, reference data, and derived datasets, sufficient to support product-centric analysis.
2. Current State Understanding
An assessment of the feasibility of producing a product-centric view across identified data assets, including identification of gaps, limitations, and constraints.
3. Product Lifecycle Definition
Documentation of current data structures, relationships, and constraints that affect the ability to represent products longitudinally across submissions and systems.
4. Product-centric Data Model
A conceptual and logical representation of a product-centric data model, including key entities, attributes, and relationships relevant to regulatory review and analysis.
5. Metadata Tagging Structure
Establishing a metadata tagging structure for unstructured submissions and identifying candidate use cases for AI-assisted processing, such as classification of document types or sections and identification of product changes across submissions.
6. AI-enabled Prototypes
Demonstration artifacts and supporting evidence sufficient to illustrate feasibility, maturity considerations, and decision tradeoffs associated with proposed approaches.
7. Findings and Roadmap Development
Documented findings and options, including recommendations, assumptions, and considerations necessary to support FDA decision-making regarding next steps.
3 Tasks and Requirements
3.1 Task 1: Data Inventory and Baseline Assessment, Current State Characterization
(Submission-Centric Environment)
3.1.1 Requirements
The Contractor shall conduct a comprehensive assessment of CTP's current submission data landscape, including the following:
1. The Contractor shall identify and document FDA-identified submission-related data sources.
2. The Contractor shall characterize each source at a level sufficient to support downstream feasibility assessments, including:
Content types (structured; semi-structured; unstructured)
Availability of metadata that supports traceability
Observed constraints that affect product-centric analysis (e.g., variability in submission packaging or organization).
3. The Contractor shall identify and document the presence of structured data capture artifacts and form-derived information that materially support product-centric analysis
(e.g., registration/listing forms; ingredient listing forms; PMTA, SE forms) and shall characterize how master file references (e.g., TPMFs) are represented in available sources.
4. The Contractor shall document observable relationships and touchpoints between sources to the extent supported by evidence (e.g., how submission artifacts or product representations appear across sources).
5. The Contractor shall identify material gaps or constraints that may limit feasibility demonstrations and communicate them to the COR.
6. The Contractor shall describe current-state organization and limitations of submission-related data as observed from available sources and FDA input.
7. The Contractor shall identify key factors that drive manual effort to locate, interpret, and compare submission information across time.
8. The Contractor shall describe observed barriers to longitudinal, product-centric visibility
(e.g., inconsistent structures; unstable identifiers; dispersed artifacts), based on evidence available.
3.1.2 Deliverables
1. Data Inventory and Baseline Assessment Summary
2. Limitations Analysis Report
Gaps in product-level visibility
Manual effort required for cross-submission analysis
Constraints on longitudinal product tracking
Potential data quality and consistency issues
3. Current State Characterization
3.2 Task 2: Product Definition, Product Lifecycle Framework and Cross-Submission
Linking
3.2.1 Requirements
Building on the findings from Task 1, the Contractor shall analyze existing data structures and develop recommendations to enable clearer linkage of multiple submissions to a single product over time; use CTP-specific product definitions and to define the relationship between tobacco products and submissions; identify data elements necessary for product linking across submissions; and identify business rules necessary for product linking across submissions.
1. The Contractor shall define a CTP-specific “product” concept for purposes of product-centric analysis and reviewer navigation, using evidence from available sources and FDA input.
2. The Contractor shall identify and document candidate attributes used to describe or distinguish a product as represented across available sources.
3. The Contractor shall identify submission-context attributes (e.g., submitting entity;
establishment context; or other available organizational context) that may be relevant to interpreting or distinguishing product representations across submissions.
4. The Contractor shall document which attributes appear consistently available and which are unreliable or inconsistent, based on observed evidence.
5. The Contractor shall create a product lifecycle framework that document:
Methodology for identifying unique products across multiple submissions
Approach for linking related submissions to common products
Strategy for tracking product changes over time
6. The Contractor shall provide conceptual and logical data models using identified tooling that includes but not limited to:
Product entities and attributes
Relationships between products, submissions, party, reviews, and other key entities or domains
Cardinality and business rules
Alignment with regulatory review needs
7. The Contractor shall Conduct workshops with CTP business stakeholders to review and validate the framework
3.2.2 Deliverables
1. Product Definition and Attribute Framework
2. Product Lifecycle Framework Document
3. Conceptual Data Model
4. Logical Data Model
5. Workshop summary reports
3.3 Task 3: Prototypes to Assist Reviewer Workflow
3.3.1 Requirements
1. Leveraging the product-centric framework and data models established in Task 1 and Task
2, the Contractor shall create one or more prototype capability(ies) that assist reviewer workflow by enabling product-centric navigation and/or structuring of selected information from submission content.
2. The Contractor shall ensure prototype outputs can be traced back to the original source documents so the Government can evaluate them.
3. The Contractor shall create a metadata tagging structure for unstructured submissions that works with AI-assisted processing and identify and document potential use cases.
4. The Contractor shall ensure prototype outputs and specifications are ready to use without requiring changes to Government workflow platforms under this contract.
5. The Contractor shall evaluate the prototype tools and document:
What each prototype does
Key limitations and conditions that significantly affect how well it works
Factors observed in the sample data that affect results
3.3.2 Deliverables
1. Metadata Tagging Structure
2. Prototype Capability Package(s), including:
Prototype outputs
Traceability examples
Interface and/or output specification (as applicable)
Demonstration materials suitable for Government evaluation
3. Prototype Evaluation Results Summary
3.4 Task 4: Proof of Concept (PoC) Demonstration and Integration Readiness Artifacts
(Optional)
3.4.1 Requirements
1. The Contractor shall demonstrate prototype capability(ies) using a Government-approved sample and provide artifacts sufficient for Government evaluation and downstream incorporation planning.
2. The Contractor shall provide integration readiness artifacts to support downstream incorporation by a Government-identified workflow implementation team, subject to
Government environment constraints, including:
a) Interface and/or output specifications;
b) Input/output definitions;
c) Dependency notes;
d) Reproducibility notes sufficient for a Government team to recreate the demonstration behavior within the Government-approved environment.
3. The Contractor shall document what the Proof of Concept (PoC) does and does not demonstrate, including constraints and prerequisites observed.
3.4.2 Deliverables
1. Proof of Concept Demonstration Artifacts.
2. Integration Readiness Package.
3.5 Task 5: Findings for Future Planning
3.5.1 Requirements
1. The Contractor shall provide findings and options to help CTP plan future decisions about product-focused data approaches and how to expand them.
2. The Contractor shall identify key dependencies, risks, and limitations found during this work that could impact future phases and implementation.
3. The Contractor shall present findings and options in a way that clearly separates:
What was observed
What the analysis shows
What to consider for the future
3.5.2 Deliverables
1. Findings and Options Report
2. Executive Brief (briefing format), if requested by the COR
3.6 Task 5: Transition-In and Closeout
3.6.1 Requirements
1. Transition-In shall begin upon contract award. The contractor shall go through an onboarding process which includes background investigations to obtain FDA badges, FDA laptops, access to FDA’s systems and network, and applicable government furnished information (GFI).
2. The Contractor shall provide a list of required software necessary to support this PWS to the
COR.
3. The Contractor shall support closeout and knowledge transfer activities, including confirming delivery of final versions of all required documentation and integration readiness artifacts produced under this PWS.
4. Implementation Team Coordination: The Contractor shall coordinate transition and closeout activities with any Government-identified workflow implementation team to support continuity and downstream incorporation planning, subject to Government decisions and approvals.
As part of the closeout activities, the Contractor shall confirm (in writing) that:
1. FDA has received draft/in-progress and final versions of all task order documentation with an index table describing where each document is located (e.g., CONOPS, SOPs, requirements specifications, design specifications, configuration management plan, etc.), to include the native format of diagrams (e.g., Visio), even those embedded in documents, have been uploaded into the FDA’s SharePoint project repository.
2. FDA has received all GFE and GFI, e.g., badges and laptops at the end of the transition period.
3. FDA has received all source code and database scripts and transferred knowledge to the Successor Contractor on how to compile from source.
4. The Contractor shall perform Data Uploads and Downloads as requested by FDA’s COR/PM
3.7 Project Management
The Contractor shall provide program/project management support for the program to include:
3.7.1 Project Plan
The Contractor shall provide a project plan that includes contract oversight objectives, performance requirements of the PWS, methods for conducting quality assessments and evaluations of deliverables, major roles and responsibilities, program and project milestones and roadmaps, and contract risk and risk mitigation strategies.
3.7.2 Kickoff Meeting
The Contractor shall conduct a kickoff meeting within 10 business days of task order award to build clarity and consensus on contract execution activities. This meeting shall include a high-level plan and approach, contract milestones and deliverables, roles and responsibilities, staffing details, and an organizational chart to introduce the contractor team to the CTP COR and key stakeholders. The
Contractor shall provide a COR-approved presentation with these items. The Contractor shall also provide the meeting minutes to the COR within three business days after the kickoff meeting and upload the minutes and presentation to the FDA’s designated repository. Coordination with the CTP
COR to determine the date, time, location, and attendees for the kickoff meeting is required.
3.7.3 Monthly Status Report
The Contractor shall provide monthly status reports to the COR/Project Managers (PMs). The Monthly
Task Order Status Report shall include:
Progress description for the task period, including the quantity and details of meetings attended and work accomplished
Deliverable completion status by requirements
Analysis of existing and potential issues, problems, and risks, including mitigation strategies and recommended resolutions by task area
Projected work activities to be accomplished during the next period by task area
An updated org chart that lists the task order team members, their roles, and management, noting key personnel with 'K' and subcontractors' personnel with an asterisk (*). Changes to the organizational structure shall be noted in the applicable Monthly Status Report (MSR).
3.7.4 Agile Roadmap
The Contractor shall provide an Agile Roadmap to the COR, reflecting the iterative implementation of the project, which includes the following information:
High-level overview of the product(s)
Articulation of the long-term strategy
Estimated timelines for features/epics and milestones
The Contractor shall maintain and update the Agile Roadmap throughout the project's lifecycle. The roadmap shall be updated as part of increment planning.
3.7.5 Staffing Plan
The Contractor shall provide a staffing plan to ensure the allocation of personnel to complete the tasks outlined in the PWS. The Contractor shall submit a roster including names, positions, contact information, and responsibilities of all staff (including subcontractors) working under this contract. Any revisions to the roster due to staffing changes shall be submitted to the COR per the direction of the
COR or CO within the specified timeline. The staffing plan shall be adaptable and responsive to meet evolving demands within this order by ensuring that staff possess diverse skill sets enabling them to effectively work on all aspects of contract scope. The FDA will not provide funding for contractor training under this order. The Contractor is expected to already possess the skills and credentials necessary to effectively perform the work.
3.7.6 Quality Assurance Surveillance Plan (QASP)
The Quality Assurance Surveillance Plan (QASP) outlines the methods that the FDA will use to monitor and evaluate the performance of the contractor to ensure compliance with contract requirements and quality standards.
The contractor shall work with the COR to establish the QASP using the following template (Table 3):
Performance Standard Acceptable Quality Level (AQL)
Method Frequency
Table 1: QASP Template
The QASP template contains the following columns:
Performance Standard: Description of the performance standard or goal
Acceptable Quality Level (AQL): The acceptable threshold of performance, typically expressed as a percentage.
Method: How performance will be measured (e.g., random sampling, 100% inspection)
Frequency: How often the performance will be evaluated (e.g., daily, weekly, monthly, per the approved project schedule)
3.7.7 DRSI Repository Maintenance and Project Management Tools The Contractor shall upload all documents and deliverables to a centralized SharePoint location provided by the COR or COR designee. The Contractor shall recommend an organized folder hierarchy in SharePoint to facilitate easy document retrieval. This proposed folder hierarchy must be approved by the COR or COR designee. Additionally, all uploaded documents must be tagged and annotated by adding comments for easy identification and searchability. Regular updates and maintenance of the
SharePoint repository will be required immediately after any document is changed to ensure all information remains up to date. Furthermore, the Contractor shall provide training to relevant stakeholders on how to navigate the SharePoint site.
The Contractor shall use Jira, Microsoft Project, or other appropriate tools selected for the project to manage tasks, track progress, requirements, and issues. The selection and use of these tools must be approved by the COR. These tools will facilitate detailed task lists, deadline monitoring, responsibility assignments, and progress reporting, ensuring that project milestones are met, and potential risks are identified. CTP also encourages the use of modern collaboration tools including Microsoft Teams and techniques that support remote and cross-functional team interactions to enhance agility.
4 Deliverables Deliverables are scalable relative to the risk, size and complexity of the project. The Contractor shall work with the FDA to determine the appropriate level of deliverables and milestones to ensure a successful outcome.
All deliverables and other Contract work products shall be solely owned by the FDA and shall not be labeled ‘copyright’, ‘proprietary’ or anything similar that might preempt the desired environment of fluid sharing and partnership. The Contractor shall provide to the FDA access to all work products including but not limited to: research, designs, code, constructs, databases, and documentation.
This section contains all the deliverables of this contract. The deliverables shall be provided in the following formats and miletones:
Section
Activity/Deliverable Format Due Date
3.1.2 Data Inventory and Baseline
Assessment Summary
Word/PowerPoint Per the approved project schedule
Limitations Analysis Report Word/PowerPoint Per the approved project schedule
Current State Characterization Word/PowerPoint Per the approved project schedule
3.2.2 Product Definition and Attribute
Framework.
Word/PowerPoint Per the approved project schedule
Product Lifecycle Framework Document
Word/PowerPoint Per the approved project schedule
Workshop summary reports Word/PowerPoint Per the approved project schedule
Conceptual Data Model Per the approved project schedule
Logical Data Model Per the approved project schedule
3.3.2 Metadata Tagging Structure Per the approved project schedule
Prototype Capability Package(s) Per the approved project schedule
Prototype Evaluation Results Summary
Word/PowerPoint Per the approved project schedule
3.4.2 Proof of Concept Demonstration
Artifacts
Per the approved project schedule
Integration Readiness Package Per the approved project schedule
3.5.2 Findings and Options Report Word/PowerPoint Per the approved project schedule
Executive Brief (briefing format), if requested by the COR
Word/PowerPoint Per the approved project schedule
Section
Activity/Deliverable Format Due Date
3.7.1 Project Plan Word 15 business days after award
3.7.2 Kickoff Meeting PowerPoint Within 10 days of the Award
3.7.3 Monthly Progress Reports Word By the 10th of each month for the previous month
3.7.4 Agile Roadmap PowerPoint 30 business days after award
3.7.5 Staffing Plan Word 15 business days after award
3.7.6 Quality Assurance Surveillance Plan
(QASP)
Word 25 business days after award
3.6.1 Final Project Close-Out Report Word Draft: Within 3 weeks of the Order expiration date
Final: By the Order expiration date
4.1 Contract Type
Firm Fixed-Price
4.2 Period of Performance
12 months
File details come from the government source that posted it. Updated .